PAOG Building CBD Pharma Capacity In Partnership With PURA - Partnership Includes PAOG Stock Dividend To PURA Shareholders
November 12 2020 - 10:13AM
InvestorsHub NewsWire
Sandusky, OH -- November 12, 2020 --
InvestorsHub NewsWire -- PAO Group, Inc. (USOTC:
PAOG) today confirmed a pharmaceutical and neurocritical
extraction partnership with Puration, Inc. (USOTC:
PURA).
PURA has acquired a 72-acre property in
Farmersville, Texas as the foundation of an innovative, hemp
processing plant. PURA is building partnerships to participate in
the project to include a pharmaceutical and neurocritical
extraction partnership with PAOG.
PURA has also established a co-packing
partnership with Alkame Holdings, Inc. (USOTC:
ALKM).
Earlier this week, PURA published a
multimedia presentation on the new initiative in
Texas:
PURA
Targets Hemp Consumer Advocates To Capture $26 Billion
Market
PAOG acquired a cannabis cultivation
operation from PURA earlier this year in a transaction that
includes issuing
PAOG shares to PURA shareholders. The target distribution
ratio calls for PURA shareholders receiving one share of PAOG for
every one share of PURA owned.
For more information on PAO Group,
visit www.paogroupinc.com
Sign up to receive the latest updates at
www.purationinc.com.
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
PAO Group,
Inc.
Jim DiPrima
888-272-6472
info@pao.group
Source: PAO Group,
Inc.
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Apr 2023 to Apr 2024